Traditional models of medical product research and development and health-care delivery are being disrupted, as incentives for research and care shift and technology opens up new opportunities. Hospitals and universities are shaking up conventional approaches to their roles. New investment models are emerging for financing early-stage R&D all the way to product approval and access. What is behind these transformations, and what will the health-care and research landscape look like for patients and investors over the next few years?

Moderator

Casey Ross National Technology Correspondent, STAT

Speakers

Ray Dorsey David M. Levy Professor of Neurology, University of Rochester

Joel Dudley Associate Professor of Genetics and Genomic Sciences and Founding Director of the Institute for Next Generation Healthcare, Icahn School of Medicine, Mount Sinai

Andrea Feinberg Chief Health Officer, Geisinger Innovation

Dan Liljenquist Senior Vice President and Chief Strategy Officer, Intermountain Healthcare